Toolkit

Annual Meeting
Information Request
Corporate Presentation

Email Alert

Sign up to join Advicenne’s Press Releases diffusion list

Sign up

Contacts

Advicenne
22 Rue de la Paix – 3ème étage
F-75002 Paris, France
+33 4 66 05 54 20
investors@advicenne.com

Financial Communications
Ulysse Communication
advicenne@ulysse-communication.com

Consilium
Advicenne@consilium-comms.com

Firm Analyst Contact Details
Gilbert Dupont Guillaume Cuvillier Equity Research Analyst
Paris, France
lifesciences@gilbertdupont.fr
Rx Securities Samir Devani Managing Director
London, United Kingdom
samir@rxsecurities.com
+44 207 993 8210
Genesta Jean-Pierre Loza Financial Analyst
Paris, France
jp.loza@aurgalys.com
+33 145 63 68 87

 

Latest news

Advicenne Reports 2021 Half Year Financial Results

Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA

Advicenne successfully raises circa €9.4m in a placement reserved to a category of persons

Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m

Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

© 2019 Advicenne

Website by B-to-B Design